Randomized Trial of Epirubicin and Cyclophosphamide Followed by Docetaxel Against Docetaxel and Cyclophosphamide in Patients With TOP2A Normal Early Breast Cancer.
Phase of Trial: Phase III
Latest Information Update: 21 Jul 2014
At a glance
- Drugs Docetaxel (Primary) ; Cyclophosphamide; Epirubicin
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms READ; READ TOP2A
- 31 Aug 2018 Biomarkers information updated
- 03 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Dec 2012 Planned end date changed from 1 Oct 2022 to 1 Dec 2022 as reported by ClinicalTrials.gov record.